Genomic clues to guide therapy in advanced prostate cancer
Official title: Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11411372 · Data updated 2026-11-12
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 14, 2001 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $384,975 |
| NIH project number | 5P50CA092629-25 |
| Project ID | NIH-11411372 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with advanced or high-risk prostate cancer who have tumor and germline DNA sequencing data available or consenting to obtain it.
✕Less likely to help
Patients without actionable genomic alterations or those unlikely to respond to targeted or immune therapies may see little to no benefit.
What this research studies
Researchers will analyze a large set of tumor and germline DNA from men with high-risk or metastatic prostate cancer to find genomic patterns linked with treatment response and progression. The goal is to use these patterns to guide choices of targeted drugs like PARP inhibitors and immune therapies. The study builds on real-world sequencing data to connect specific genetic changes with clinical outcomes, aiming to personalize care for patients facing advanced disease.
Why it matters
Potential benefit: If successful, patients could receive more effective, tailored treatments based on their genetic profile.
How similar studies have gone: Prior work shows genomic profiling can predict responses to PARP inhibitors and immunotherapies in some patients, but broader and more precise predictors are still needed.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Solit, David B. — Sloan-Kettering Inst Can Research
- Study coordinator: Solit, David B.
Related research
Other NIH-funded projects on the same topics.
-
Genetic markers that predict treatment response in advanced prostate cancer
This project looks at whether tumor and inherited DNA changes can show which men with advanced prostate cancer are most likely to benefit from targeted drugs and immunotherapy.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.